Regulation - Opsumit

Filter

Current filters:

Opsumit

Popular Filters

Actelion gains approval in Australia for Opsumit in PAH

Actelion gains approval in Australia for Opsumit in PAH

07-02-2014

Swiss biotech firm Actelion (SIX: ATLN) has received approval of Opsumit (macitentan) for the treatment…

ActelionAustraliaBiotechnologyCardio-vascularOpsumitRegulation

Actelion’s PAH drug Opsumit approved in EU

Actelion’s PAH drug Opsumit approved in EU

22-12-2013

Switzerland-based Actelion has received European Commission approval for Opsumit (macitentan), a novel…

ActelionBiotechnologyEuropeOpsumitRegulationRespiratory and Pulmonary

Actelion receives Health Canada approval of Opsumit for PAH

Actelion receives Health Canada approval of Opsumit for PAH

13-11-2013

Swiss biotech firm Actelion (SIX: ATLN) says that Canada’s regulator Health Canada has approved its…

ActelionCanadaCardio-vascularNorth AmericaOpsumitPharmaceuticalRegulation

Positive EMA/CHMP opinions for Actelion and Lundbeck

Positive EMA/CHMP opinions for Actelion and Lundbeck

27-10-2013

At its October month-end meeting, the European Medicines Agency’s Committee for Medicinal Products…

ActelionBiotechnologyBrintellixEuropeLundbeckNeurologicalOpsumitPharmaceuticalRegulationRespiratory and Pulmonary

US FDA gives nod to Actelion’s PAH drug Opsumit

US FDA gives nod to Actelion’s PAH drug Opsumit

21-10-2013

The US Food and Drug Administration has approved Actelion's pulmonary arterial hypertension drug Opsumit…

ActelionBiotechnologyCardio-vascularNorth AmericaOpsumitRegulation

FDA staffers back riociguat approval, but with modified dose

05-08-2013

On Tuesday (August 6), the US Food and Drug Administration's Renal Drugs Advisory Committee will discuss…

ActelionAdempasBayerNorth AmericaOpsumitPharmaceuticalRegulationRespiratory and PulmonaryriociguatTracleer

Actelion filing for EU approval of Opsumit accepted

23-11-2012

Switzerland-based Actelion (SIX: ATLN) says that it has submitted a Marketing Authorisation Application…

ActelionBiotechnologyEuropemacitentanOpsumitRegulationRespiratory and Pulmonary

Actelion files for US approval of Opsumit for PAH

23-10-2012

Europe's largest biotech company Actelion (SIX: ATLN) said yesterday that it has submitted a New Drug…

ActelionBiotechnologymacitentanNorth AmericaOpsumitRegulationResearchRespiratory and Pulmonary

Back to top